Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics S.A.    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
6(c) 5.94(c) 6.98(c) 7.59(c) 7.32(c) Last
1 177 728 559 706 2 058 742 1 423 663 709 552 Volume
+7.33% -1.00% +17.51% +8.74% -3.56% Change
More quotes
Financials
Sales 2020 12,5 M 15,1 M 15,1 M
Net income 2020 -16,7 M -20,1 M -20,1 M
Net cash position 2020 16,7 M 20,2 M 20,2 M
P/E ratio 2020 -12,3x
Yield 2020 -
Sales 2021 15,6 M 18,9 M 18,9 M
Net income 2021 -16,1 M -19,4 M -19,4 M
Net Debt 2021 5,15 M 6,22 M 6,22 M
P/E ratio 2021 -15,0x
Yield 2021 -
Capitalization 290 M 349 M 350 M
EV / Sales 2020 21,9x
EV / Sales 2021 18,9x
Nbr of Employees 25
Free-Float 95,4%
More Financials
Company
GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2019, the company had a portfolio of 2 products, including 1 in phase III clinical development (GS010 for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis... 
More about the company
Notations Surperformance© of GenSight Biologics S.A.
Trading Rating : Investor Rating :
More Ratings
All news about GENSIGHT BIOLOGICS S.A.
11/04GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ Marketing Authorisation A..
AQ
11/03GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ® Marketing Authorisation ..
PU
11/03GENSIGHT BIOLOGICS : Reports Validation of LUMEVOQ® Marketing Authorisation Appl..
BU
10/23GENSIGHT BIOLOGICS S A : successfully raises EUR25 million in an oversubscribed ..
AQ
10/22GENSIGHT BIOLOGICS S A : Securities Note
PU
10/22GENSIGHT BIOLOGICS S A : Amendment to the 2019 Universal Registration Document
PU
10/22GENSIGHT BIOLOGICS S A : launches a capital increase of approximately EUR25 mill..
AQ
10/22GENSIGHT BIOLOGICS S A : successfully raises €25 million in an oversubscribed pr..
PU
10/22GENSIGHT BIOLOGICS S A : Successfully Raises €25 Million in an Oversubscribed Pr..
BU
10/21GENSIGHT BIOLOGICS S A : launches a capital increase of approximately €25 millio..
PU
10/16GENSIGHT BIOLOGICS S A : Reports Cash Position as of September 30, 2020 and Prov..
AQ
10/15GENSIGHT BIOLOGICS S A : Appoints Elsy Boglioli to its Board of Directors
AQ
10/15GENSIGHT BIOLOGICS S A : Reports Cash Position as of September 30, 2020 and Prov..
PU
10/15GENSIGHT BIOLOGICS S A : Reports Cash Position as of September 30, 2020 and Prov..
BU
10/14GENSIGHT BIOLOGICS S A : Appoints Elsy Boglioli to its Board of Directors
PU
More news
News in other languages on GENSIGHT BIOLOGICS S.A.
11/03Rien ne va plus, les jeux ne sont pas encore faits
11/03EN DIRECT DES MARCHES : BNP Paribas, EssilorLuxottica, Carrefour, Adecco, HelloF..
11/03GENSIGHT BIOLOGICS : annonce la validation de la demande d'autorisation de mise ..
10/22EN DIRECT DES MARCHES : Atos, Eurofins, Hermès, Pernod Ricard, STMicro, Thales, ..
10/22La peur du reconfinement
More news
Chart GENSIGHT BIOLOGICS S.A.
Duration : Period :
GenSight Biologics S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,23 €
Last Close Price 7,32 €
Spread / Highest target 91,3%
Spread / Average Target 39,8%
Spread / Lowest Target -8,47%
EPS Revisions
Managers
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Chairman
Thomas Gidoin Chief Financial Officer
Magali Taiel Chief Medical Officer
José-Alain Sahel Director
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS S.A.194.57%359
GILEAD SCIENCES, INC.-5.94%76 052
VERTEX PHARMACEUTICALS5.18%59 224
REGENERON PHARMACEUTICALS36.91%54 464
WUXI APPTEC CO., LTD.57.04%38 135
BIONTECH SE236.51%29 915